» Articles » PMID: 33758856

Mutational Escape from the Polyclonal Antibody Response to SARS-CoV-2 Infection is Largely Shaped by a Single Class of Antibodies

Abstract

Monoclonal antibodies targeting a variety of epitopes have been isolated from individuals previously infected with SARS-CoV-2, but the relative contributions of these different antibody classes to the polyclonal response remains unclear. Here we use a yeast-display system to map all mutations to the viral spike receptor-binding domain (RBD) that escape binding by representatives of three potently neutralizing classes of anti-RBD antibodies with high-resolution structures. We compare the antibody-escape maps to similar maps for convalescent polyclonal plasma, including plasma from individuals from whom some of the antibodies were isolated. The plasma-escape maps most closely resemble those of a single class of antibodies that target an epitope on the RBD that includes site E484. Therefore, although the human immune system can produce antibodies that target diverse RBD epitopes, in practice the polyclonal response to infection is dominated by a single class of antibodies targeting an epitope that is already undergoing rapid evolution.

Citing Articles

Genetic diversity and evolutionary convergence of cryptic SARS- CoV-2 lineages detected via wastewater sequencing.

Gregory D, Trujillo M, Rushford C, Flury A, Kannoly S, San K PLoS Pathog. 2022; 18(10):e1010636.

PMID: 36240259 PMC: 9604950. DOI: 10.1371/journal.ppat.1010636.


Comprehensive Deep Mutational Scanning Reveals the Immune-Escaping Hotspots of SARS-CoV-2 Receptor-Binding Domain Targeting Neutralizing Antibodies.

Tsai K, Lee Y, Tseng T Front Microbiol. 2021; 12:698365.

PMID: 34335530 PMC: 8319916. DOI: 10.3389/fmicb.2021.698365.


SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants.

Tea F, Stella A, Aggarwal A, Darley D, Pilli D, Vitale D PLoS Med. 2021; 18(7):e1003656.

PMID: 34228725 PMC: 8291755. DOI: 10.1371/journal.pmed.1003656.

References
1.
Zhang W, Davis B, Chen S, Sincuir Martinez J, Plummer J, Vail E . Emergence of a Novel SARS-CoV-2 Variant in Southern California. JAMA. 2021; 325(13):1324-1326. PMC: 7879386. DOI: 10.1001/jama.2021.1612. View

2.
Schoofs T, Barnes C, Suh-Toma N, Golijanin J, Schommers P, Gruell H . Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. Immunity. 2019; 50(6):1513-1529.e9. PMC: 6591006. DOI: 10.1016/j.immuni.2019.04.014. View

3.
Voloch C, da Silva Francisco Jr R, de Almeida L, Cardoso C, Brustolini O, Gerber A . Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil. J Virol. 2021; 95(10). PMC: 8139668. DOI: 10.1128/JVI.00119-21. View

4.
Planas D, Bruel T, Grzelak L, Guivel-Benhassine F, Staropoli I, Porrot F . Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat Med. 2021; 27(5):917-924. DOI: 10.1038/s41591-021-01318-5. View

5.
Letko M, Marzi A, Munster V . Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020; 5(4):562-569. PMC: 7095430. DOI: 10.1038/s41564-020-0688-y. View